Regulatory data workflow
Capture, map, verify, and route approved information with source references and an explicit exception queue.
Inspect the workflowAI workflows for pharma teams that need the evidence to stay visible.
Durability Labs designs bounded automation around approved sources, representative tests, named review, and the deployment constraints your environment actually has.
The workflow prepares and coordinates. People retain the business, professional, and regulated decisions.
Synthetic workflow / DL-001 Human review open
Source set Preloaded synthetic dossier Public demonstration only
01PermitSynthetic set
02MapSource linked
03Verify2 exceptions
04ReviewNamed owner
05TracePending
Privacy first
Define where data goes, who can see it, and how it leaves.
Measured accuracy
Test representative output and report limits instead of promising perfection.
Human control
Keep correction, rejection, approval, and accountable decisions with people.
Clear provenance
Connect material output to sources, changes, exceptions, and reviewers.
Build the smallest workflow that can prove its value.
The studio starts with one costly bottleneck. Before anything confidential moves, the scope names the source set, intended use, environment, acceptance test, people, evidence, and exclusions.
- 01 Permit
Approve the source, environment, access, retention, and intended use.
- 02 Capture
Retrieve and structure only the material authorized for the workflow.
- 03 Verify
Check representative output against sources and hold exceptions for review.
- 04 Approve
Give named people the evidence and context needed to decide.
- 05 Trace
Record the source, change, exception, reviewer, and final state.
Pharma is where the method is deepest.
We apply the control model to regulatory data, documents, trackers, and ex-US operations without treating one workflow as a substitute for qualified judgment.
Ex-US readiness
Frame target-market assumptions, dossier reuse, localization gaps, responsibilities, dependencies, and the next decision.
Review the sprintRegulatory operations
Scope bounded dossier, submission, authority-response, labeling, lifecycle, or fractional-operations work.
Review the scopeQA and marketing operations
Founder-led discovery only. Document, evidence, routing, and data-hygiene problems remain proof-gated; accountable decisions stay with client roles.
Discuss a proof-gated need with SaadInspect the workflow before you scope the work.
The pharma dossier demo uses synthetic material to show source structure, drafting, review states, and the boundary between a public demonstration and a production engagement.
Get Instant Demo AccessMaterialSynthetic and preloaded
FilesDo not upload client information
DecisionHuman-owned
ProductionSeparately scoped and evidenced
The operating boundary is part of the build.
A model name, deployment label, or audit log does not establish privacy, security, compliance, validation, or fitness for use. Those claims depend on the complete system, intended use, evidence, and accountable owners.
Review Governance- Durability
- Prepare, map, test, coordinate, and preserve the evidence defined in scope.
- Client owner
- Authorize intended use, sources, systems, access, and operating decisions.
- Qualified reviewer
- Interpret and approve regulated conclusions where the work requires that role.
- Automation
- Never receives independent release, medical, legal, quality, safety, or regulatory authority.
Proof is labeled by what it can actually establish.
Today the public evidence is a synthetic demonstration, inspectable operating method, and bounded offer material—not invented clients, universal deployments, or quantified outcomes.
Evidence state matters.
Every proof surface should say whether it is a synthetic demonstration, operating-method evidence, sourced research, or a client-approved case.
Inspect the Proof RegisterEvidenceWhat it establishesState
Pharma dossier demoProduct direction and review modelSynthetic
Workflow railOperating method and decision boundaryMethod
Client outcomesNo public evidence or permission recordedNot claimed
Read the operating logic behind the studio.
Short, controlled notes for buyers deciding how to frame sensitive automation before technology selection begins.
Human-owned AI workflowsHow to automate preparation without moving decision accountability. Deployment labels are not assuranceWhat client-controlled, on-premises, hybrid, and open-source-capable still require. A synthetic demo is a boundary, not a weaknessWhat buyers can inspect before production evidence exists.
Bring one workflow—not a transformation program.
We will determine whether the problem is bounded enough to test, which evidence is needed, who keeps the decision, and which deployment directions are realistic.